Literature DB >> 28839082

Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?

Samuel L Aitken1,2, Farnaz Foolad3, Patrick M McDaneld3.   

Abstract

Entities:  

Keywords:  Enterobacter; antimicrobial stewardship; bacteremia; cefepime; meropenem

Mesh：

Substances：

Year:  2017        PMID： 28839082      PMCID： PMC5571301          DOI： 10.1128/AAC.01160-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  3 in total

1.  Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders.

Authors:  M Soledad Cepeda; Ray Boston; John T Farrar; Brian L Strom
Journal:  Am J Epidemiol       Date:  2003-08-01       Impact factor: 4.897

2.  Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae.

Authors:  Lucy Cheng; Brian C Nelson; Monica Mehta; Nikhil Seval; Sarah Park; Marla J Giddins; Qiuhu Shi; Susan Whittier; Angela Gomez-Simmonds; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

3.  Risk factors for relapse or persistence of bacteraemia caused by Enterobacter spp.: a case-control study.

Authors:  Patrick N A Harris; Anna M Peri; Anita M Pelecanos; Carly M Hughes; David L Paterson; John K Ferguson
Journal:  Antimicrob Resist Infect Control       Date:  2017-01-21       Impact factor: 4.887
  3 in total
  3 in total

Review 1.  A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.

Authors:  Pranita D Tamma; Yohei Doi; Robert A Bonomo; J Kristie Johnson; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

2.  Reply to Aitken et al., "Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?"

Authors:  Lucy Cheng; Brian C Nelson; Monica Mehta; Qiuhu Shi; Angela Gomez-Simmonds; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Risk Factors of Death in Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacterales in Patients with Neoplasia.

Authors:  Tiago da Cunha Ferreira; Ianick Souto Martins
Journal:  Infect Drug Resist       Date:  2021-08-11       Impact factor: 4.003
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.